TAMSIN BLANCHARD: Open Payments
NPI 1700240835 · SEBASTIAN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$978 in 29 payments from 12 companies in 2025. Trend: 2023 $1,178 · 2024 $404 · 2025 $978
Food & beverage: $961Education: $17
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $334 |
| Grifols USA, LLC | 3 | $147 |
| Lilly USA, LLC | 1 | $124 |
| GlaxoSmithKline, LLC. | 4 | $87 |
| Insmed, Inc. | 3 | $73 |
| Pulmonx Corporation | 2 | $60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Electromed, Inc. | 3 | $28 |
| GENZYME CORPORATION | 1 | $27 |
| Merck Sharp & Dohme LLC | 1 | $26 |
Products named: Prolastin-C Liquid, FASENRA, BREZTRI, MOUNJARO, CHARTIS CATHETER, NUCALA, Arikayce, TEZSPIRE.
Industry payments across FL — which companies pay providers there.
